Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy

Statins for secondary prevention: might less in fact be more?

Nature Reviews Endocrinology volume 7, pages 131–132 (2011)Cite this article

Subjects

Statin therapy following myocardial infarction is a pillar of the secondary prevention approach. However, defining a maximally beneficial dosing strategy requires attention to both cardiovascular outcomes and to the potentially unsavory clinical adverse effects of high-dose therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376, 1658–1669 (2010).

  2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22 (2002).

  3. Neuvonen, P. J., Kantola, T. & Kivistö, K. T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63, 332–41 (1998).

    Article  CAS  Google Scholar 

  4. Roten, L., Schoenenberger, R. A., Krähenbühl, S. & Schlienger, R. G. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother. 38, 978–981(2004).

    Article  Google Scholar 

  5. Hansten, P. D. Possible risks to patients receiving statins combined with other medications. J. Am. Coll. Cardiol. 41, 519–520 (2003).

    Google Scholar 

  6. Armitage, J., Baigent, C., Chen, Z. & Landray, M. A randomized trial of the long-term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant [online], http://clinicaltrials.gov/ct2/show/NCT00461630 (2010).

  7. Brown, B. G, McBride, R., Boden, W.E. & Probstfield, J., AIM HIGH: niacin plus statin to prevent vascular events [online], http://clinicaltrials.gov/ct/show/NCT00120289 (2010).

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Blalock 524C, 600 North Wolfe Street, Baltimore, 21287, MD, USA

    Daniel Muñoz & Roger S. Blumenthal

Authors
  1. Daniel Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger S. Blumenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger S. Blumenthal.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muñoz, D., Blumenthal, R. Statins for secondary prevention: might less in fact be more?. Nat Rev Endocrinol 7, 131–132 (2011). https://doi.org/10.1038/nrendo.2011.17

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2011.17

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing